NCT04363853View on ClinicalTrials.gov

Tocilizumab Treatment in Patients With COVID-19

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

December 1, 2025

Study Completion Date

December 31, 2025

Conditions
Sars-CoV2
Interventions
DRUG

Tocilizumab 20 MG/ML

We study the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection.

Trial Locations (1)

14080

National Cancer Institute of Mexico, Mexico City

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Instituto Nacional de Cancerologia de Mexico

OTHER